Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 31, 2012
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus
Christine Hamann, Martina Rauner, Yvonne Höhna, et al.
Bone
|
August 6, 2014
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats
Marina Stolina, Denise Dwyer, Qing-Tian Niu, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 19, 2016
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
Sang Wan Kim, Yanhui Lu, Elizabeth A Williams, et al.
Calcified Tissue International
|
June 23, 2018
Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury
Wei Zhao, Xiaodong Li, Yuanzhen Peng, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
December 31, 2015
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta
Ingo Grafe, Stefanie Alexander, Tao Yang, et al.
European Journal of Endocrinology
|
May 18, 2026
Navepegritide Combined with Lonapegsomatropin for the Treatment of Children with Achondroplasia: 52-Week Results from the Phase 2 COACH Trial
Ciara M McDonnell, Melita Irving, Line Aagaard Nolting, et al.
Endocrinology
|
July 8, 2011
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats
Xiaodong Li, Michael S Ominsky, Kelly S Warmington, et al.
Journal of Dental Research
|
April 5, 2018
Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss
M Liu, P Kurimoto, J Zhang, et al.
Bone
|
January 2, 2016
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats
Scott Taylor, Michael S Ominsky, Rong Hu, et al.
Nature Medicine
|
January 24, 2007
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra, Marina Stolina, Karin Polzer, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 31, 2012
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus
Christine Hamann, Martina Rauner, Yvonne Höhna, et al.
Bone
|
August 6, 2014
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats
Marina Stolina, Denise Dwyer, Qing-Tian Niu, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 19, 2016
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
Sang Wan Kim, Yanhui Lu, Elizabeth A Williams, et al.
Calcified Tissue International
|
June 23, 2018
Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury
Wei Zhao, Xiaodong Li, Yuanzhen Peng, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
December 31, 2015
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta
Ingo Grafe, Stefanie Alexander, Tao Yang, et al.
European Journal of Endocrinology
|
May 18, 2026
Navepegritide Combined with Lonapegsomatropin for the Treatment of Children with Achondroplasia: 52-Week Results from the Phase 2 COACH Trial
Ciara M McDonnell, Melita Irving, Line Aagaard Nolting, et al.
Endocrinology
|
July 8, 2011
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats
Xiaodong Li, Michael S Ominsky, Kelly S Warmington, et al.
Journal of Dental Research
|
April 5, 2018
Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss
M Liu, P Kurimoto, J Zhang, et al.
Bone
|
January 2, 2016
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats
Scott Taylor, Michael S Ominsky, Rong Hu, et al.
Nature Medicine
|
January 24, 2007
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra, Marina Stolina, Karin Polzer, et al.
Page
of 9